Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tacrolimus: a new immunosuppressive agent

P A Kelly1, G J Burckart, R Venkataramanan

  • 1Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburg, PA 15261, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|July 15, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary.

Clinical pharmacology and therapeutics·2017
Same author

The Influence of Race and Common Genetic Variations on Outcomes After Pediatric Heart Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.

Clinical pharmacology and therapeutics·2015
Same author

A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.

Clinical pharmacology and therapeutics·2015
Same author

Failed Pediatric Drug Development Trials.

Clinical pharmacology and therapeutics·2015
Same author

Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.

Clinical pharmacology and therapeutics·2012
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Tacrolimus, an effective immunosuppressant, prevents organ transplant rejection by inhibiting T-cell activity. It offers a viable alternative to cyclosporine, with major side effects including nephrotoxicity and neurotoxicity.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Tacrolimus is a novel immunosuppressant medication.
  • It is used for preventing organ rejection after transplantation.
  • Cyclosporine is a current standard for immunosuppression.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, drug interactions, clinical efficacy, and adverse effects of tacrolimus.
  • To compare tacrolimus with cyclosporine in organ transplantation.
  • To evaluate tacrolimus as an alternative immunosuppressant.

Main Methods:

  • Review of existing literature on tacrolimus.
  • Analysis of clinical trial data from liver, kidney, heart, lung, and intestinal transplantation.
  • Examination of tacrolimus's mechanism of action, pharmacokinetics, and adverse effects.

Related Experiment Videos

Main Results:

  • Tacrolimus inhibits interleukin-2 expression in T cells, suppressing T-cell growth and proliferation.
  • Oral bioavailability is 5-67% with a half-life of 4-41 hours.
  • Tacrolimus is metabolized by cytochrome P-450 3A4, leading to drug interactions.
  • Clinical trials demonstrate tacrolimus efficacy in liver transplantation, comparable to cyclosporine.
  • Tacrolimus shows promise in other transplant types as a cyclosporine alternative.
  • Nephrotoxicity and neurotoxicity are identified as major adverse effects.

Conclusions:

  • Tacrolimus is an effective immunosuppressant for preventing organ transplant rejection.
  • It serves as a valuable alternative to cyclosporine for primary immunosuppression and rescue therapy.
  • Further research is needed for tacrolimus use in non-liver transplantations.